Evidence map›Paper›PMID 42248607›Full record

ArticleJournal for immunotherapy of cancer2026

CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.

Sara K Silbert, Flavia Gava, Bonnie Yates, Alexander W Rankin, Joseph M Rocco, Lipei Shao, Alexandra Dreyzin, Yihua Cai, Chelsea Lamplugh, Kyu Lee Han and 16 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Sara K SilbertPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.
Flavia GavaPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.
Bonnie YatesPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.
Alexander W RankinPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0002-6089-9279
Joseph M RoccoNational Institute of Allergy and Infectious Disease, NIH, Bethesda, MD, USA.
Lipei ShaoCenter for Cellular Engineering, National Institutes of Health, Bethesda, Maryland, USA.
Alexandra DreyzinPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.
Yihua CaiCenter for Cellular Engineering, National Institutes of Health, Bethesda, Maryland, USA.
Chelsea LamplughPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.
Kyu Lee HanCenter for Cellular Engineering, National Institutes of Health, Bethesda, Maryland, USA.
Michaela ProchazkovaCenter for Cellular Engineering, National Institutes of Health, Bethesda, Maryland, USA.
Lauren LittlePediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.
Toni FoleyPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.
Hari SankaranBiometric Research Program, National Cancer Institute, Bethesda, Maryland, USA.
Kathryn MartinCenter for Cellular Engineering, National Institutes of Health, Bethesda, Maryland, USA.
Pamela GarcesCenter for Cellular Engineering, National Institutes of Health, Bethesda, Maryland, USA.
Ping JinCenter for Cellular Engineering, National Institutes of Health, Bethesda, Maryland, USA.
Christopher D ChienPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0002-4871-5262
Naomi TaylorPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0002-2459-4558
Terry J FryUniversity of Colorado Denver Children's Hospital Colorado Research Institute, Aurora, Colorado, USA.
Constance M YuanLaboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA.
Hao-Wei WangLaboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA.
David F StroncekCenter for Cellular Engineering, National Institutes of Health, Bethesda, Maryland, USA.
Steven L HighfillCenter for Cellular Engineering, National Institutes of Health, Bethesda, Maryland, USA.
Haneen ShalabiPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.
Nirali N ShahPediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA nirali.shah@nih.gov.ORCID http://orcid.org/0000-0002-8474-9080

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiantigen targeting chimeric antigen receptor (CAR) T cells have emerged as a strategy to mitigate antigen escape observed after single antigen targeting therapy. Our initial experience with a bivalent CD19.22.BBζ CAR T-cell construct in children, adolescents and young adults (CAYA) with B-cell acute lymphoblastic leukemia (B-ALL) demonstrated limitations in CD22 recognition, but a tolerable safety profile and efficacy prompted further evaluation. This trial enrolled patients between the ages of 3-39 with relapsed/refractory B-ALL. Following dose-escalation, patients who enrolled at the recommended phase 2 dose (RP2D) of 3×10

Indexed as

Antigens, CD19Immunotherapy, AdoptivePrecursor B-Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 2AdolescentAdultChildChild, PreschoolFemaleHumansMaleYoung AdultAntigens, CD19CD22 protein, humanReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 2Adoptive cell therapy - ACTChimeric antigen receptor - CARHematologic Malignancies

Identifiers

PMID42248607
PMCPMC13250228

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.